VEGF inhibitor-induced hypertension: A crucial line of evidence comes from oncology, where drugs targeting the VEGF pathway—such as VEGF inhibitors like bevacizumab or VEGFR inhibitors like sunitinib and pazopanib—are widely used. Here, KDR is linked to hypertensive disorder.